Secondary Progressive Multiple Sclerosis Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
SUMMARY
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Secondary Progressive Multiple Sclerosis Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Secondary Progressive Multiple Sclerosis Drug market segmented into
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Secondary Progressive Multiple Sclerosis Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Secondary Progressive Multiple Sclerosis Drug market segmented into
- Inebilizumab
- GLX-1112
- DC-TAB
- Etomoxir
- IB-MS
- Others
- Hospital
- Clinic
- Others
- North America [U.S., Canada, Mexico]
- Europe [Germany, UK, France, Italy, Rest of Europe]
- Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
- South America [Brazil, Argentina, Rest of Latin America]
- Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
- AB Science SA
- Actelion Ltd
- Biogen, Inc.
- F. Hoffmann-La Roche Ltd.
- Genzyme Corporation
- Glialogix, Inc.
- Immune Response BioPharma, Inc.
- Innate Immunotherapeutics Ltd
- Kyorin Pharmaceutical Co., Ltd.
- Mallinckrodt Plc
- MedDay SA
- MedImmune, LLC
- Merck KGaA
- Meta-IQ ApS
- Novartis AG
- Opexa Therapeutics, Inc.
- Xenetic Biosciences (UK) Limited
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG INDUSTRY
2.1 Summary about Secondary Progressive Multiple Sclerosis Drug Industry
2.2 Secondary Progressive Multiple Sclerosis Drug Market Trends
2.2.1 Secondary Progressive Multiple Sclerosis Drug Production & Consumption Trends
2.2.2 Secondary Progressive Multiple Sclerosis Drug Demand Structure Trends
2.3 Secondary Progressive Multiple Sclerosis Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Inebilizumab
4.2.2 GLX-1112
4.2.3 DC-TAB
4.2.4 Etomoxir
4.2.5 IB-MS
4.2.6 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Inebilizumab
5.2.2 GLX-1112
5.2.3 DC-TAB
5.2.4 Etomoxir
5.2.5 IB-MS
5.2.6 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Inebilizumab
6.2.2 GLX-1112
6.2.3 DC-TAB
6.2.4 Etomoxir
6.2.5 IB-MS
6.2.6 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Inebilizumab
7.2.2 GLX-1112
7.2.3 DC-TAB
7.2.4 Etomoxir
7.2.5 IB-MS
7.2.6 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Inebilizumab
8.2.2 GLX-1112
8.2.3 DC-TAB
8.2.4 Etomoxir
8.2.5 IB-MS
8.2.6 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Inebilizumab
9.2.2 GLX-1112
9.2.3 DC-TAB
9.2.4 Etomoxir
9.2.5 IB-MS
9.2.6 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 AB Science SA
10.1.2 Actelion Ltd
10.1.3 Biogen, Inc.
10.1.4 F. Hoffmann-La Roche Ltd.
10.1.5 Genzyme Corporation
10.1.6 Glialogix, Inc.
10.1.7 Immune Response BioPharma, Inc.
10.1.8 Innate Immunotherapeutics Ltd
10.1.9 Kyorin Pharmaceutical Co., Ltd.
10.1.10 Mallinckrodt Plc
10.1.11 MedDay SA
10.1.12 MedImmune, LLC
10.1.13 Merck KGaA
10.1.14 Meta-IQ ApS
10.1.15 Novartis AG
10.1.16 Opexa Therapeutics, Inc.
10.1.17 Xenetic Biosciences (UK) Limited
10.2 Secondary Progressive Multiple Sclerosis Drug Sales Date of Major Players (2017-2020e)
10.2.1 AB Science SA
10.2.2 Actelion Ltd
10.2.3 Biogen, Inc.
10.2.4 F. Hoffmann-La Roche Ltd.
10.2.5 Genzyme Corporation
10.2.6 Glialogix, Inc.
10.2.7 Immune Response BioPharma, Inc.
10.2.8 Innate Immunotherapeutics Ltd
10.2.9 Kyorin Pharmaceutical Co., Ltd.
10.2.10 Mallinckrodt Plc
10.2.11 MedDay SA
10.2.12 MedImmune, LLC
10.2.13 Merck KGaA
10.2.14 Meta-IQ ApS
10.2.15 Novartis AG
10.2.16 Opexa Therapeutics, Inc.
10.2.17 Xenetic Biosciences (UK) Limited
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG INDUSTRY
2.1 Summary about Secondary Progressive Multiple Sclerosis Drug Industry
2.2 Secondary Progressive Multiple Sclerosis Drug Market Trends
2.2.1 Secondary Progressive Multiple Sclerosis Drug Production & Consumption Trends
2.2.2 Secondary Progressive Multiple Sclerosis Drug Demand Structure Trends
2.3 Secondary Progressive Multiple Sclerosis Drug Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Inebilizumab
4.2.2 GLX-1112
4.2.3 DC-TAB
4.2.4 Etomoxir
4.2.5 IB-MS
4.2.6 Others
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospital
4.3.2 Clinic
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Inebilizumab
5.2.2 GLX-1112
5.2.3 DC-TAB
5.2.4 Etomoxir
5.2.5 IB-MS
5.2.6 Others
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospital
5.3.2 Clinic
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Inebilizumab
6.2.2 GLX-1112
6.2.3 DC-TAB
6.2.4 Etomoxir
6.2.5 IB-MS
6.2.6 Others
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospital
6.3.2 Clinic
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Inebilizumab
7.2.2 GLX-1112
7.2.3 DC-TAB
7.2.4 Etomoxir
7.2.5 IB-MS
7.2.6 Others
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospital
7.3.2 Clinic
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Inebilizumab
8.2.2 GLX-1112
8.2.3 DC-TAB
8.2.4 Etomoxir
8.2.5 IB-MS
8.2.6 Others
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospital
8.3.2 Clinic
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Inebilizumab
9.2.2 GLX-1112
9.2.3 DC-TAB
9.2.4 Etomoxir
9.2.5 IB-MS
9.2.6 Others
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospital
9.3.2 Clinic
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 AB Science SA
10.1.2 Actelion Ltd
10.1.3 Biogen, Inc.
10.1.4 F. Hoffmann-La Roche Ltd.
10.1.5 Genzyme Corporation
10.1.6 Glialogix, Inc.
10.1.7 Immune Response BioPharma, Inc.
10.1.8 Innate Immunotherapeutics Ltd
10.1.9 Kyorin Pharmaceutical Co., Ltd.
10.1.10 Mallinckrodt Plc
10.1.11 MedDay SA
10.1.12 MedImmune, LLC
10.1.13 Merck KGaA
10.1.14 Meta-IQ ApS
10.1.15 Novartis AG
10.1.16 Opexa Therapeutics, Inc.
10.1.17 Xenetic Biosciences (UK) Limited
10.2 Secondary Progressive Multiple Sclerosis Drug Sales Date of Major Players (2017-2020e)
10.2.1 AB Science SA
10.2.2 Actelion Ltd
10.2.3 Biogen, Inc.
10.2.4 F. Hoffmann-La Roche Ltd.
10.2.5 Genzyme Corporation
10.2.6 Glialogix, Inc.
10.2.7 Immune Response BioPharma, Inc.
10.2.8 Innate Immunotherapeutics Ltd
10.2.9 Kyorin Pharmaceutical Co., Ltd.
10.2.10 Mallinckrodt Plc
10.2.11 MedDay SA
10.2.12 MedImmune, LLC
10.2.13 Merck KGaA
10.2.14 Meta-IQ ApS
10.2.15 Novartis AG
10.2.16 Opexa Therapeutics, Inc.
10.2.17 Xenetic Biosciences (UK) Limited
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
LIST OF TABLES
Table Secondary Progressive Multiple Sclerosis Drug Product Type Overview
Table Secondary Progressive Multiple Sclerosis Drug Product Type Market Share List
Table Secondary Progressive Multiple Sclerosis Drug Product Type of Major Players
Table Brief Introduction of AB Science SA
Table Brief Introduction of Actelion Ltd
Table Brief Introduction of Biogen, Inc.
Table Brief Introduction of F. Hoffmann-La Roche Ltd.
Table Brief Introduction of Genzyme Corporation
Table Brief Introduction of Glialogix, Inc.
Table Brief Introduction of Immune Response BioPharma, Inc.
Table Brief Introduction of Innate Immunotherapeutics Ltd
Table Brief Introduction of Kyorin Pharmaceutical Co., Ltd.
Table Brief Introduction of Mallinckrodt Plc
Table Brief Introduction of MedDay SA
Table Brief Introduction of MedImmune, LLC
Table Brief Introduction of Merck KGaA
Table Brief Introduction of Meta-IQ ApS
Table Brief Introduction of Novartis AG
Table Brief Introduction of Opexa Therapeutics, Inc.
Table Brief Introduction of Xenetic Biosciences (UK) Limited
Table Products & Services of AB Science SA
Table Products & Services of Actelion Ltd
Table Products & Services of Biogen, Inc.
Table Products & Services of F. Hoffmann-La Roche Ltd.
Table Products & Services of Genzyme Corporation
Table Products & Services of Glialogix, Inc.
Table Products & Services of Immune Response BioPharma, Inc.
Table Products & Services of Innate Immunotherapeutics Ltd
Table Products & Services of Kyorin Pharmaceutical Co., Ltd.
Table Products & Services of Mallinckrodt Plc
Table Products & Services of MedDay SA
Table Products & Services of MedImmune, LLC
Table Products & Services of Merck KGaA
Table Products & Services of Meta-IQ ApS
Table Products & Services of Novartis AG
Table Products & Services of Opexa Therapeutics, Inc.
Table Products & Services of Xenetic Biosciences (UK) Limited
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Region 2021f-2026f
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f
Table Secondary Progressive Multiple Sclerosis Drug Product Type Overview
Table Secondary Progressive Multiple Sclerosis Drug Product Type Market Share List
Table Secondary Progressive Multiple Sclerosis Drug Product Type of Major Players
Table Brief Introduction of AB Science SA
Table Brief Introduction of Actelion Ltd
Table Brief Introduction of Biogen, Inc.
Table Brief Introduction of F. Hoffmann-La Roche Ltd.
Table Brief Introduction of Genzyme Corporation
Table Brief Introduction of Glialogix, Inc.
Table Brief Introduction of Immune Response BioPharma, Inc.
Table Brief Introduction of Innate Immunotherapeutics Ltd
Table Brief Introduction of Kyorin Pharmaceutical Co., Ltd.
Table Brief Introduction of Mallinckrodt Plc
Table Brief Introduction of MedDay SA
Table Brief Introduction of MedImmune, LLC
Table Brief Introduction of Merck KGaA
Table Brief Introduction of Meta-IQ ApS
Table Brief Introduction of Novartis AG
Table Brief Introduction of Opexa Therapeutics, Inc.
Table Brief Introduction of Xenetic Biosciences (UK) Limited
Table Products & Services of AB Science SA
Table Products & Services of Actelion Ltd
Table Products & Services of Biogen, Inc.
Table Products & Services of F. Hoffmann-La Roche Ltd.
Table Products & Services of Genzyme Corporation
Table Products & Services of Glialogix, Inc.
Table Products & Services of Immune Response BioPharma, Inc.
Table Products & Services of Innate Immunotherapeutics Ltd
Table Products & Services of Kyorin Pharmaceutical Co., Ltd.
Table Products & Services of Mallinckrodt Plc
Table Products & Services of MedDay SA
Table Products & Services of MedImmune, LLC
Table Products & Services of Merck KGaA
Table Products & Services of Meta-IQ ApS
Table Products & Services of Novartis AG
Table Products & Services of Opexa Therapeutics, Inc.
Table Products & Services of Xenetic Biosciences (UK) Limited
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Region 2021f-2026f
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f
LIST OF FIGURES
Figure Global Secondary Progressive Multiple Sclerosis Drug Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of AB Science SA 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Actelion Ltd 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Biogen, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of F. Hoffmann-La Roche Ltd. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Genzyme Corporation 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Glialogix, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Immune Response BioPharma, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Innate Immunotherapeutics Ltd 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Kyorin Pharmaceutical Co., Ltd. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Mallinckrodt Plc 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of MedDay SA 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of MedImmune, LLC 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Merck KGaA 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Meta-IQ ApS 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Novartis AG 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Opexa Therapeutics, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Xenetic Biosciences (UK) Limited 2017-2020e
Figure Global Secondary Progressive Multiple Sclerosis Drug Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of AB Science SA 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Actelion Ltd 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Biogen, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of F. Hoffmann-La Roche Ltd. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Genzyme Corporation 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Glialogix, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Immune Response BioPharma, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Innate Immunotherapeutics Ltd 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Kyorin Pharmaceutical Co., Ltd. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Mallinckrodt Plc 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of MedDay SA 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of MedImmune, LLC 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Merck KGaA 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Meta-IQ ApS 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Novartis AG 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Opexa Therapeutics, Inc. 2017-2020e
Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Xenetic Biosciences (UK) Limited 2017-2020e
